CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 944 enrolled
Drug / intervention
CP-690,550 +1 moredrug
Likely dose
CP-690,550 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01470612
NCT01470612Phase 3Completed
CompareCT.gov

A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Pfizer·interventional·Posted Nov 11, 2011·Updated Sep 17, 2021

In Brief

A Phase 3 clinical trial evaluating CP-690,550 for Ulcerative Colitis. Completed, enrolled 944 participants across 252 sites in 31 countries.

Detailed Summary

This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, New Zealand, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2011
Enrollment StartOct 1, 2012
Primary CompletionAug 6, 2020
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 14.6 years ago

Interventions

CP-690,550drug

5 mg tablets, BID, for at least 12 months

CP-690,550drug

10 mg tablets, BID, for at least 12 months